Voronoi Inc banner
V

Voronoi Inc
KOSDAQ:310210

Watchlist Manager
Voronoi Inc
KOSDAQ:310210
Watchlist
Price: 316 000 KRW 6.04% Market Closed
Market Cap: ₩5.8T

Voronoi Inc
Minority Interest

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Voronoi Inc
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
V
Voronoi Inc
KOSDAQ:310210
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Minority Interest
₩144.1B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
5%
SK Bioscience Co Ltd
KRX:302440
Minority Interest
₩248.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Minority Interest
₩699.4m
CAGR 3-Years
33%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Minority Interest
₩9.2B
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
N/A
A
ABL Bio Inc
KOSDAQ:298380
Minority Interest
₩2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Voronoi Inc
Glance View

Market Cap
5.8T KRW
Industry
Biotechnology

Voronoi, Inc. engages in the manufacture of novel kinase inhibitors and target protein degrader drugs. The company is headquartered in Incheon, Incheon. The company went IPO on 2022-06-24. The firm is principally engaged in the technology transfer of new drug candidates prior to electroclinical clinical trials. The firm is principally engaged in the research and development of kinase inhibitor as well as others. In addition, the Company is also engaged in the building and supply of new drug development platforms based on artificial intelligence (AI) and research results.

Intrinsic Value
10 111.03 KRW
Overvaluation 97%
Intrinsic Value
Price ₩316 000
V

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett